Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01278225 · ClinicalTrials.gov registry record

Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain

A clinical trial of Pain and Peripheral Neuropathy, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
80
Enrollment target
1
Study location

NCT01278225 is a study of Pain and Peripheral Neuropathy that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01278225, a study of Pain and Peripheral Neuropathy, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to learn if using a non-invasive therapy called "neurofeedback training" can help teach patients ways to modify their own brain waves to decrease the perception of pain and improve quality of life.

Interventions

  • BEHAVIORAL EEG biofeedback (BF) Group
  • BEHAVIORAL Wait-List Control (WLC) Group
  • BEHAVIORAL Follow UP Questionnaires

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2011-02
Est. Completion 2027-04-01

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT01278225

The ClinicalTrials.gov registry entry for NCT01278225 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 3 interventions - of which EEG biofeedback (BF) Group is the first listed.

NCT01278225 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01278225 about?

NCT01278225 is a clinical study titled "Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain". The goal of this study is to learn if using a non-invasive therapy called "neurofeedback training" can help teach patients ways to modify their own brain waves to decrease the perception of pain and improve quality of life.

What is the current status of trial NCT01278225?

This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2011-02. Estimated completion is 2027-04-01.

What conditions does trial NCT01278225 study?

This clinical trial studies the following conditions: Pain, Peripheral Neuropathy.

What interventions are being tested in trial NCT01278225?

The interventions under investigation include: EEG biofeedback (BF) Group (BEHAVIORAL), Wait-List Control (WLC) Group (BEHAVIORAL), Follow UP Questionnaires (BEHAVIORAL).

Who is sponsoring clinical trial NCT01278225?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01278225 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.